ORIGINAL RESEARCH article

Front. Cardiovasc. Med.

Sec. Cardiovascular Pharmacology and Drug Discovery

Disproportionality Analysis of Adverse Events Associated with Endothelin Receptor Antagonists Based on the FDA Adverse Event Reporting System (FAERS)

  • Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China

Article metrics

View details

193

Views

The final, formatted version of the article will be published soon.

Abstract

Background: Endothelin receptor antagonists (ERAs)—bosentan, ambrisentan, macitentan—are first-line for pulmonary arterial hypertension (PAH), yet real-world comparative safety data are scarce. Objective: Mine FAERS to identify and contrast potential ADEs across the three ERAs. Methods: Retrospective disproportionality analysis of ICSRs (Q1 2004–Q2 2025) followed READUS-PV; MedDRA-coded events were screened with ROR, PRR, BCPNN, MGPS (≥2 algorithms required for signal) and TTO curves. Results: 35 112, 48 411, 29 877 reports were extracted for bosentan, ambrisentan, macitentan (female 74%, 18–65 y). Ambrisentan contributed 42.7% of cases. Labelled signals—peripheral oedema, dyspnoea, liver dysfunction, anaemia—were confirmed; novel signals included jaw pain, pulmonary thrombosis, gout, hypokalaemia, hypotension. Most events arose within the first year; >50% of flagged PTs occurred ≥12 months after initiation. Conclusion: The study validates known toxicities, ranks their relative intensity and flags new ADEs, supporting individualized ERA selection and prolonged monitoring of hepatic, renal, haemodynamic and electrolyte status.

Summary

Keywords

Adverse DrugEvents, Disproportionality analysis, Endothelin receptor antagonists, pulmonary arterial hypertension, Signal detection

Received

25 September 2025

Accepted

10 February 2026

Copyright

© 2026 Li, Jianting, Yin, He, Wang, Li, Han and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lizhu Han; Bian Yuan

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Share article

Article metrics